Myopia, Myopia Progression
Conditions
Keywords
axial length, cycloplegic spherical equivalent autorefraction
Brief summary
The goal of this clinical trial is to learn if spectacle films using Active Reconfiguration in Retinal Encoding of Spatio-Temporal (A.R.R.E.S.T.®) signal technology works to slow down the rate of myopia progression in myopic children. The first stage of the trial compares spectacle films using A.R.R.E.S.T.® technology to single vision spectacle lenses in myopic children and the second stage looks at the rate of myopia progression in children while wearing spectacle films using A.R.R.E.S.T.® technology. The main questions to answer are: Do spectacle films using A.R.R.E.S.T.® technology slow down the rate of axial length growth? Do spectacle films using A.R.R.E.S.T.® technology slow down the rate of increase in myopic refractive error? Researchers will compare spectacle films using A.R.R.E.S.T.® technology to a single vision spectacle lens for 12 months followed by assessing spectacle films using A.R.R.E.S.T.® technology for slowing down myopia progression for another 12 months. Participants will initially be randomly allocated to wear either spectacle films using A.R.R.E.S.T.® technology or single vision spectacle lenses and visit the clinic on seven occasions over a 12 month period. After completing the first 12 months, all participants will wear spectacle films using A.R.R.E.S.T.® technology and visit the clinic on five occasions over the second 12 month period.
Detailed description
The aims of this clinical trial are: 1. To compare the rate of myopia progression as measured by change from the Stage 1 Dispensing visit (up to 40 days from Baseline), in axial length and the change from Baseline in the cycloplegic spherical equivalent autorefraction between spectacle films using A.R.R.E.S.T.® technology (test) and single vision spectacle lenses (control). Myopic children (6-14 years of age) will be randomly allocated to wear either test control. 2. To assess the rate of myopia progression as measured by change from the Stage 2 Dispensing visit (up to 40 days from the Stage 1: 12-months visit), in axial length and the change from the Stage 1: 12-months visit in the cycloplegic spherical equivalent autorefraction while wearing spectacle films using A.R.R.E.S.T.® technology. The myopic children from Stage 1 will enter Stage 2. The overall trial duration, including follow-up period, is expected to be approximately 30 months. Each participant's duration is expected to be approximately 24 months. The visits are: Stage 1: Baseline, Dispensing, 1-month, 3-months, 6 months,9-months, and 12-months. Stage 2: Dispensing, 3-months, 6 months,9-months, and 12-months. All procedures performed at these visits are standard, non-invasive clinical tests.
Interventions
Standard single vision spectacle lens
DEVICEA.R.R.E.S.T. spectacle film
A.R.R.E.S.T. spectacle film
Sponsors
nthalmic Pty Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 14 Years
Healthy volunteers
No
Inclusion criteria
* Be between 6 to 14 years old inclusive at time of enrolment. * Have: * Read the Informed Assent. * Been explained the Informed Assent. * Indicated an understanding of the Informed Assent. * Signed the Informed Assent. * Have their parent / legal guardian. * Read the Informed Consent. * Been explained the Informed Consent. * Indicated an understanding of the Informed Consent. * Signed the Informed Consent. * Along with their parent/legal guardian, be capable of comprehending the nature of the study and be willing to adhere to the study requirements. * Along with their parent/legal guardian, agree to maintain the visit and prescribed wearing schedule. * Agree to wear the study spectacles for a minimum of 5 days/week, 6 hours/day for the duration of the study and to inform the investigator if their schedule is interrupted. * Be in good general health, based on parent's/legal guardian's knowledge. * Have best-corrected high contrast visual acuity of 0.10 logMAR (Snellen: 20/25, 6/7.6; Decimal: 0.80) or better in each eye. * Meet the following criteria determined by cycloplegic autorefraction at Baseline: * -5.00 D ≤ spherical equivalent ≤ -0.75 D and sphere component ≤ -0.50 DS * -1.50 DC ≤ astigmatic component ≤ 0 DC * \|Spherical equivalent anisometropia\| ≤ 1.00 D.
Exclusion criteria
* Participant is currently an active participant in another study or was an active participant in another study within 30 days prior to this study. * Current or prior use of interventions intended for myopia control, including but not limited to: * Optical devices: * Bifocal / multifocal spectacles. * Bifocal / multifocal contact lenses. * Orthokeratology. * Pharmacological agents: * Atropine with a concentration \> 0.01%. * Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study. * Pirenzepine. * Participant born earlier than 30 weeks or weighed \< 1500 g at birth. * A verbal report from the participant's parent / legal guardian is sufficient. * Habitual use of a systemic or topical medication that may alter normal ocular findings / is known to affect a participant's ocular health / physiology either in an adverse or beneficial manner at enrolment and / or during the clinical trial. * A known allergy to sodium fluorescein, benoxinate, proparacaine, tropicamide, or cyclopentolate. * Strabismus as determined by cover test at distance (≥ 3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions. * Known ocular or systemic disease, such as but not limited to: * Diabetes. * Graves' disease. * Glaucoma. * Uveitis. * Scleritis. * Auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus. * Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to: * Persistent pupillary membrane. * Vitreous haemorrhage. * Cataract. * Central corneal scarring. * Eyelid haemangiomas. * Marfan's syndrome. * Down's syndrome. * Ehler's-Danlos syndrome. * Stickler's syndrome. * Ocular albinism. * Retinopathy of prematurity. * Keratoconus or irregular cornea. The Investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Axial Length | Stage 1: Dispensing Visit (up to 40 days from Baseline), then 1-, 3-, 6-, 9-, and 12- months after Dispensing Visit. Stage 2: Dispensing Visit (up to 40 days from Stage 1: 12-months:), then 3-, 6-, 9-, and 12- months after Dispensing Visit. | Difference in change from Stage 1 dispensing in axial length between test and control. The change in axial length from the Stage 2 dispensing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cycloplegic spherical equivalent autorefraction | Stage 1: Baseline, then 6- and 12- months after Dispensing Visit (up to 40 days from Baseline). Stage 2: Stage 1: 12-months visit, then 6- and 12-months after Stage 2 Dispensing Visit (up to 40 days from Stage 1: 12 months visit). | Difference in change from Baseline in cycloplegic spherical equivalent autorefraction between test and control. The change in cycloplegic spherical equivalent autorefraction from the Stage 1: 12-months visit. |
| Visual performance as measured by high contrast visual acuity at 6 m | Stage 1: Dispensing Visit (up to 40 days from Baseline), then 1-, 3-, 6-, 9-, and 12-months after Dispensing Visit. Stage 2: Dispensing Visit (up to 40 days from Stage 1: 12-months visit), then 3-, 6-, 9-, and 12-months after Dispensing Visit. | Difference in high contrast visual acuity at 6 m between test and control. High contrast visual acuity at 6 m while wearing spectacle films using A.R.R.E.S.T.® technology. |
| Visual performance as measured by a non validated questionnaire based on a 1-10 numeric rating scale | Stage 1: 1-, 3-, 6-, 9-, and 12-months after Dispensing Visit (up to 40 days from Baseline). Stage 2: 3-, 6-, 9-, and 12-months after Dispensing Visit (up to 40 days from Stage 2: 12-months Visit). | Difference in subjective visual performance between test and control. Subjective visual performance while wearing spectacle films using A.R.R.E.S.T.® technology. |
Countries
Vietnam
Outcome results
None listed